Emerging treatments
Passive immunotherapy
There are no clinical trials of passive immunotherapy in humans with Sin Nombre virus (SNV). It has been noted that patients presenting with hantavirus cardiopulmonary syndrome (HCPS) with high levels of neutralizing antibody had better survival.[69] Immunotherapy in animal models seems to be protective against SNV infection.[43]
Human immune plasma
Human immune plasma has been shown to reduce the case-fatality rate for Andes virus from 32% to 14%.[70]
Favipiravir
In the hamster-adapted SNV-infection model, the experimental antiviral favipiravir reduced tissue viral antigen levels.[71]
Use of this content is subject to our disclaimer